Achieve Life Sciences Inc(ACHV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.55 | Insider Own | 32.16% | Shs Outstand | 102.7M | Perf Week | 5.22% |
| Market Cap | 0.70B | Forward P/E | - | EPS next Y | 53.58% | Insider Trans | -0.06% | Shs Float | 69.8M | Perf Month | -10.92% |
| Enterprise Value | 0.53B | PEG | - | EPS next Q | -0.2 | Inst Own | 56.43% | Short Float | 25.51% | Perf Quarter | 8.73% |
| Income | -0.11B | P/S | - | EPS this Y | -16.8% | Inst Trans | 51.82% | Short Ratio | 12.33 | Perf Half Y | 65.06% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -91.46% | Short Interest | 17.81M | Perf YTD | 37.83% |
| Book/sh | -0.14 | P/C | 3.76 | EPS past 3/5Y | 32.06% 25.38% | ROE | -844.99% | 52W High | -20.72% ($8.64) | Perf Year | 43.31% |
| Cash/sh | 1.82 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 161.45% ($2.62) | Perf 3Y | 74.74% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.14% | Gross Margin | - | Volatility(W/M) | 4.78% 5.59% | Perf 5Y | -17.27% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.38 | Perf 10Y | -99.28% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | EPS Q/Q | -118.05% | Profit Margin | - | RSI (14) | 46.31 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | Sales Q/Q | - | SMA20 | -0.72% ($6.9) | Beta | 2.4 | Target Price | $14.58 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/11 | SMA50 | -8.7% ($7.5) | Rel Volume | 0.67 | Prev Close | $6.93 |
| Employees | 28 | LT Debt/Eq | - | EPS/Sales Surpr. | -385.14% - | SMA200 | 21.74% ($5.63) | Avg Volume(3M) | 1.44M | Price | $6.85 |
| IPO | 1995/10/12 | Option/Short | Yes/Yes | Trades | 5618 | Volume | 963,731 | Change | -1.15% |
Achieve Life Sciences (ACHV) is a late-stage clinical pharmaceutical company developing treatments for nicotine dependence. Its lead candidate, cytisicline, targets both the smoking cessation and e-cigarette (vaping) cessation markets, and this small-cap biotech has entered the FDA new drug review stage in the United States.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
ACHV has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -16.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -17.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #188 of 594 in the industry
Based on market cap of $705M.
FDMT#187 4D Molecular Therapeutics Inc $714M PER - ACHV#188 Achieve Life Sciences Inc $705M PER - 
IAM#189 Iambic Therapeutics Inc $701M PER - 
SLDB#190 Solid Biosciences Inc $695M PER - 
DSGN#191 Design Therapeutics Inc $693M PER - 
FAQ
What kind of company is ACHV?
ACHV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACHV?
The market cap of ACHV is approximately $705M, ranking 2,880 within its sector.
What is the 52-week high and low for ACHV?
ACHV has recorded a 52-week high of $8.64 and a low of $2.62.
